Core Insights - Vitarion, a clinical-stage biotechnology company, focuses on developing transformative therapies for neurodegenerative diseases, inflammatory immune diseases, metabolic diseases, and rare diseases [1][3] - The company announced the appointment of Wang Shuzhan, Managing Director of Yunfeng Fund, to its board, highlighting his extensive experience in investment and operational leadership in the life sciences sector [1][2] - Vitarion has a diverse pipeline of projects targeting key pathogenic mechanisms related to aging, degenerative changes, metabolic dysfunction, and inflammation, with ongoing clinical studies for several candidates [3] Group 1 - Vitarion is dedicated to developing innovative therapies for various diseases, including neurodegenerative and rare diseases [1][3] - The company has established a robust scientific foundation and an exciting R&D pipeline since its inception in 2017 [3] - Wang Shuzhan's addition to the board is expected to complement the existing board's expertise and support the clinical development of first-in-class or best-in-class innovations [1][2] Group 2 - The company is currently conducting clinical research on multiple projects, including SARM1 inhibitor SIR2501, NAMPT agonist SIR4156, and RIPK1 inhibitor SIR9900, while also advancing preclinical studies [3] - Vitarion was recognized in the 2025 Endpoints 11 list of the most promising biotechnology startups, indicating its potential in the industry [3]

Core Insights - Vitarion, a clinical-stage biotechnology company, focuses on developing transformative therapies for neurodegenerative diseases, inflammatory immune diseases, metabolic diseases, and rare diseases [1][3] - The company announced the appointment of Wang Shuzhan, Managing Director of Qiming Venture Partners, to its board, enhancing its leadership with his extensive experience in the life sciences sector [1][2] - Vitarion has a diverse pipeline of projects, including clinical studies on SARM1 inhibitor SIR2501, NAMPT agonist SIR4156, and RIPK1 inhibitor SIR9900, while also advancing preclinical research [3] Company Overview - Vitarion was established in 2017 and has built a robust scientific foundation with a focus on key pathogenic mechanisms related to aging, degenerative changes, metabolic dysfunction, and inflammation [3] - The company was recognized in the 2025 Endpoints 11 list of most promising biotechnology startups, indicating its potential in the industry [3]

Core Insights - Vitarion is a clinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative diseases, inflammatory and immune diseases, metabolic disorders, and rare diseases [2] Group 1: Company Overview - Vitarion was established in 2017 and has developed a diversified project pipeline targeting key drivers of aging, degenerative changes, metabolic dysfunction, and inflammation [2] - The company is currently conducting clinical studies on NAMPT activator SIR4156, SARM1 inhibitor SIR2501, and RIPK1 inhibitor SIR9900, while also advancing preclinical research [2] - Vitarion was recognized in the 2025 Endpoints 11 list of most promising biotechnology startups [2] Group 2: Upcoming Conference - Vitarion will present a scientific poster titled "Targeting NAMPT Activation for the Treatment of Neuromuscular and Mitochondrial Diseases" at the NAD and Health: Opportunities and Challenges 2026 international conference in Copenhagen from March 23 to 25, 2026 [1] - The conference will explore whether regulating nicotinamide adenine dinucleotide (NAD⁺) metabolism can extend human healthspan and prevent or modulate age-related diseases [1] - The event aims to establish a framework for translating key findings from basic scientific research into therapies for neurodegenerative diseases, endocrine disorders, and cardiovascular metabolic diseases [1]